Precision therapy for HER2-positive breast cancer
10.3760/cma.j.cn.115807-20230220-00045
- VernacularTitle:人表皮生长因子受体2阳性乳腺癌的精准治疗
- Author:
Xin DONG
1
;
Tongtong ZHANG
;
Xiaodong XIE
;
Fang ZHANG
Author Information
1. 滨州医学院烟台附属医院肿瘤科，烟台 264100
- Keywords:
Breast cancer;
Human epidermal growth factor receptor 2
- From:
Chinese Journal of Endocrine Surgery
2023;17(2):138-142
- CountryChina
- Language:Chinese
-
Abstract:
Human epidermal growth factor receptor 2 (HER2) -positive breast cancer is prone to metastasis and has a poor prognosis. In the context of the booming development of anti-HER2 targeted therapy, HER2-positive breast cancer has reduced recurrence and metastasis and improved prognosis. However, there are still some HER2-positive breast cancer patients who cannot benefit from anti-HER2-targeted therapy and continue to develop recurrent metastasis. Neoadjuvant therapy, surgical treatment, and the full range of adjuvant and palliative therapies enable HER2-positive breast cancer to benefit from them. Scholars from home and abroad have explored the treatment of HER2-positive breast cancer and have achieved some results. In this article, we review the current status and development of HER2-positive breast cancer treatment.
